Login / Signup

Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.

Renata UrsuDidier MailletCatherine BelinChristine MoroniStefania CuzzubboVictoria VernierLila Sirven-VillarosChristophe CarreauRoberta Di BlasiCatherine ThieblemontAntoine F Carpentier
Published in: Neurology (2022)
In conclusion, no significant neurocognitive or neurologic disorders were observed in this cohort of patients, 2 years after treatment with anti-CD19 CAR T cells.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • bipolar disorder
  • stem cells
  • cell therapy
  • patient reported